Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 466-470

  Yoshimura, Reiji ^a   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Katsuki, Asuka ^a   Atake, Kiyokazu ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Hamilton Rating Scale for Depression; interleukin 6; major depressive disorder; selective serotonin reuptake inhibitor; serotonin transporter

Indexed keywords

INTERLEUKIN 6; PAROXETINE; SERTRALINE;

ADULT; AGED; ALLELE; ARTICLE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

HAMILTON RATING SCALE FOR DEPRESSION; INTERLEUKIN-6; MAJOR DEPRESSIVE DISORDER; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER;

ADULT; AGED; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884151160     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2333     Document Type: Article

References (23)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders Text Revision. Washington D.C. USA.
2. Banks WA, Kastin AJ, Broadwell RD,. 1995. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2: 241-248.
3. Bull SJ, Huezo-Diaz P, Binder EB, et al,. 2009. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14: 1095-104.
4. Caruncho HJ, Rivera-Baltanás T,. 2012. Biomarker of depression. Rev Neurol 50: 470-476.
5. Chrousos GP,. 1995. The hypothalamic-pituitary-adrenal axis and immune mediated inflammation. N Engl J Med 332: 1351-1362.
6. Dhabhar FS, Burke HM, Epel ES, Mellon SH,. 2009. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 43: 962-969.
7. Dentino AN, Piper CF, Rao KMK,. 1999. Association of interleukin-6 and other biological variables with depression in older people living in the community. Am J Geriatr Soc 47: 6-11.
8. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
9. Hannestad J, DellaGioia N, Bloch M,. 2011. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36: 2452-9.
10. Hanisch UK,. 2002. Microglia as a source and target of cytokines. Glia 40: 140-155.
11. Hayley S, Poulter MO, Merali Z, Anisman H,. 2005. The pathogenesis of clinical depression: stressor-and cytokine-induced alteration of neuroplasticity. Neuroscience 135: 659-678.
12. Hiles SA, Baker AL, de Malmanche T, Attia J,. 2012. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Bevav Immun 26: 1180-1186.
13. Kemp AH, Gordon E, Rush AJ, et al,. 2008. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging and genetic measures. CNS Spectrum 13: 1066-1086.
14. Kronfol Z, Remick DG,. 2000. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157: 683-694.
15. Lesch K, Bengel D, Helis A, et al,. 1996. Association of anxiety related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
16. Levinson D,. 2009. Genetics of major depression. In:, Gotlib IH, Hammen CL, (eds.) Handbook of Depression, 2nd ed. The Guildford Press: New York; 165-186.
17. Mastorakos G, Weber JS, Magiakou GA, Gunn H, Chrousos GP,. 1994. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79: 934-939.
18. Mitoma M, Yoshimura R, Sugita T, et al,. 2008. Stress at work alters serum brain-derived neurotrophic factor (BDNF) and plasma 3-methoxy-4- hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress? Prog Neuropsychopharmacol Biol Psychiatry 32: 679-685.
19. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM,. 2000. Reciprocal actions of interleukin-6 and brain derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci 12: 1891-1899.
20. O'Brien SM, Scott LV, Dinan T,. 2004. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Him Psychopharmacol 19: 397-403.
21. Su S, Zhao J, Bremner JD, et al,. 2009. Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet 2: 614-20.
22. Yoshimura R, Mitoma M, Sugita A, et al,. 2007. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1034-1037.
23. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J,. 2009. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 44: 722-726.